These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16807514)

  • 1. Beta blockers in portal hypertension. Are they really a good option?
    López-Méndez E; Uribe M
    Ann Hepatol; 2006; 5(2):86-91. PubMed ID: 16807514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complications of cirrhosis. I. Portal hypertension.
    Bosch J; García-Pagán JC
    J Hepatol; 2000; 32(1 Suppl):141-56. PubMed ID: 10728801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis.
    Merkel C; Bolognesi M; Sacerdoti D; Bombonato G; Bellini B; Bighin R; Gatta A
    Hepatology; 2000 Nov; 32(5):930-4. PubMed ID: 11050041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic prevention of variceal bleeding and rebleeding.
    Baiges A; Hernández-Gea V; Bosch J
    Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
    J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approaches in the pharmacologic treatment of portal hypertension.
    Bosch J; García-Pagán JC; Feu F; Luca A; Fernández M; Pizcueta P; Rodés J
    J Hepatol; 1993; 17 Suppl 2():S41-5. PubMed ID: 8098342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study.
    Hicken BL; Sharara AI; Abrams GA; Eloubeidi M; Fallon MB; Arguedas MR
    Aliment Pharmacol Ther; 2003 Jan; 17(1):145-53. PubMed ID: 12492744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of variceal rebleeding.
    Bosch J; García-Pagán JC
    Lancet; 2003 Mar; 361(9361):952-4. PubMed ID: 12648985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The portal hypertension syndrome: etiology, classification, relevance, and animal models.
    Bosch J; Iwakiri Y
    Hepatol Int; 2018 Feb; 12(Suppl 1):1-10. PubMed ID: 29064029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variceal bleeding : pharmacological treatment and prophylactic strategies.
    Villanueva C; Balanzó J
    Drugs; 2008; 68(16):2303-24. PubMed ID: 18973395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.
    Villanueva C; Aracil C; Colomo A; Hernández-Gea V; López-Balaguer JM; Alvarez-Urturi C; Torras X; Balanzó J; Guarner C
    Gastroenterology; 2009 Jul; 137(1):119-28. PubMed ID: 19344721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes!
    Merkel C; Montagnese S
    Eur J Intern Med; 2011 Feb; 22(1):1-4. PubMed ID: 21238883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variceal bleeding and portal hypertensive gastropathy.
    Dagher L; Burroughs A
    Eur J Gastroenterol Hepatol; 2001 Jan; 13(1):81-8. PubMed ID: 11204818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing first variceal hemorrhage in cirrhosis.
    Albillos A
    J Clin Gastroenterol; 2007; 41 Suppl 3():S305-11. PubMed ID: 17975481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.
    La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J
    Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blockers for prophylaxis of bleeding from esophageal varices in cirrhotic portal hypertension. Review of the literature.
    Zoller WG; Gross M
    Eur J Med Res; 1996 Jun; 1(9):407-16. PubMed ID: 9353240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP).
    Merkel C; Marin R; Enzo E; Donada C; Cavallarin G; Torboli P; Amodio P; Sebastianelli G; Sacerdoti D; Felder M; Mazzaro C; Beltrame P; Gatta A
    Lancet; 1996 Dec 21-28; 348(9043):1677-81. PubMed ID: 8973428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone.
    Merkel C; Sacerdoti D; Bolognesi M; Enzo E; Marin R; Bombonato G; Angeli P; Gatta A
    Hepatology; 1997 Jul; 26(1):34-9. PubMed ID: 9214449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage.
    Bosch J
    P R Health Sci J; 2000 Mar; 19(1):57-67. PubMed ID: 10761206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review: pharmacotherapeutic agents in the treatment of portal hypertension.
    Lebrec D
    J Gastroenterol Hepatol; 1997 Feb; 12(2):159-66. PubMed ID: 9083918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.